Goodwill and Other Intangible Assets Intangible Assets (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended			9 Months Ended																		9 Months Ended	12 Months Ended		9 Months Ended			3 Months Ended		3 Months Ended
	Mar. 29, 2014		Mar. 30, 2013	Mar. 29, 2014		Mar. 30, 2013	Jun. 29, 2013	Mar. 29, 2014 In Process Research and Development [Member]	Jun. 29, 2013 In Process Research and Development [Member]	Mar. 29, 2014 Trade Names And Trademarks [Member]	Jun. 29, 2013 Trade Names And Trademarks [Member]	Mar. 29, 2014 Distribution And License Agreements [Member]	Jun. 29, 2013 Distribution And License Agreements [Member]	Mar. 29, 2014 Developed Product Technology/Formulation and Product Rights [Member]	Jun. 29, 2013 Developed Product Technology/Formulation and Product Rights [Member]	Mar. 29, 2014 Customer Relationships [Member]	Jun. 29, 2013 Customer Relationships [Member]	Mar. 29, 2014 Noncompete Agreements [Member]	Jun. 29, 2013 Noncompete Agreements [Member]	Mar. 29, 2014 Trademarks [Member]	Jun. 29, 2013 Trademarks [Member]	Mar. 29, 2014 Paddock Laboratories Inc [Member]	Jun. 29, 2013 Paddock Laboratories Inc [Member] In Process Research and Development [Member]	Feb. 11, 2013 Paddock Laboratories Inc [Member] In Process Research and Development [Member]	Mar. 29, 2014 Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain] In Process Research and Development [Member]	Mar. 30, 2013 Rosemont Pharmaceuticals Ltd. [Domain] Developed Product Technology/Formulation and Product Rights [Member]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain] Developed Product Technology/Formulation and Product Rights [Member]	Mar. 30, 2013 Rosemont Pharmaceuticals Ltd. [Domain] Noncompete Agreements [Member]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain] Noncompete Agreements [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Definite-lived intangible assets																										$ 148.2
Write-off of in process research and development	0		0	6.0		0																4.0			2.0
Other intangible assets acquired																								13.0		148.2	11.2		114.6		1.5
Acquired intangible assets, average estimated useful lives (in years)																							12 years					7 years		3 years
Intangible assets subject to amortization, Gross	7,683.4			7,683.4			1,473.7					6,324.3	192.7	925.4	896.8	370.9	358.2	15.2	13.3	47.6	12.7
Intangible assets subject to amortization, Accumulated Amortization	502.0			502.0			316.1					120.0	28.9	277.7	204.6	91.0	72.4	8.4	6.0	4.9	4.2
Intangible assets not subject to amortization								9.8	27.8	59.0	57.0
Total other intangible assets, Gross	7,752.2			7,752.2			1,558.5
Intangible assets amortization expense	107.4		24.6	181.1		65.0
Finite-Lived Intangible Assets, Future Amortization Expense [Abstract]
2014	109.0	[1]		109.0	[1]
2015	442.0			442.0
2016	452.0			452.0
2017	449.0			449.0
2018	$ 441.0			$ 441.0

[1] Reflects remaining three months of fiscal 2014.